Navigation Links
Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™
Date:8/31/2011

MELBOURNE, Australia, Aug. 31, 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd has completed treatment of subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.

This Phase 2b trial is evaluating the efficacy, safety and tolerability of two dose levels of a single application of DeOvo™ compared to vehicle. The trial consists of treating 132 healthy subjects with head lice infestation, 2 years of age and older, in two study centers in the United States.

Hatchtech's proprietary product DeOvo™ is a topical formulation of a known metalloprotease inhibitor which targets proteases that are key to biological processes involved in insect hatch and survival.

Hatchtech Chairman Dr Paul Kelly commented: "We continue to be encouraged by Hatchtech's progress with its next generation head lice product DeOvo™ in line with our business objectives. The recruitment and treatment of subjects in this study has been achieved and we look forward to receiving results of the study later this year as planned."

"In the US it is estimated that 6-12 million people, mainly children aged 3-12 years, are infested each year with head lice (Pediculus humanus capitis). With the emergence of drug resistant lice and often poor efficacy of existing products, this under-served market represents a substantial commercial opportunity." Company Contact

Media InquiriesDr Paul Kelly

Dr Vern BowlesChairman

Chief Scientific Officer+61 (2) 8205-7379

+61 (0) 400 673 938pkelly@one-ventures.com

vbowles@hatchtech.com.auAbout the TrialThe following information is provided in accord with the AusBiotech/ASX Code of Best Practice for Reporting by Life Sciences Companies.Name of TrialHa02-003Blinding StatusDouble-blindPlacebo ControlledRandomized, vehicle-controlledDesignP
'/>"/>

SOURCE Hatchtech Pty Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 UBM Medica US ... a new online community and information resource for neurologists ... and treat their patients with neurological disorders . ... an aging population, necessitates greater access to dedicated information ... statistics on neurological conditions include: , 1 ...
(Date:7/23/2014)... July 23, 2014 Research and Markets ... (ECG) Market by Product, End-user & by Lead Type ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... into three major segments, namely, holter monitor, resting, and ... valued at $3,683 million in 2013 and is poised ...
(Date:7/23/2014)... -- The Centers for Medicare & Medicaid Services (CMS) ... Organization (QIN-QIO) contract to a partnership led by the ... 1, WVMI will launch Quality Insights Quality Innovation Network ... Pennsylvania , Delaware , ... will engage providers and the community in multiple, data-driven ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
... June 29 Max Neeman International, India ,s ... extended the platform to provide expert CDISC (Clinical Data Interchange Standards ... data conversion, implementation of CDISC standards and CDISC compliance checks. , ... CDISC SDTM (Standard ...
... IRVINE, Calif. , June 29 Avrio Biopharmaceuticals, ... of David A. Gelber as the Director of Manufacturing. ... production systems and ensuring clients receive high quality service in a ... , ...
Cached Medicine Technology:Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model 2Avrio Appoints David L. Gelber to Director of Manufacturing 2Avrio Appoints David L. Gelber to Director of Manufacturing 3
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July ... may not be as effective against cystic fibrosis as ... that one of the medications might stop the other ... definitive, and there,s still hope for the medications known ... the study,s senior author. "The development of drugs ...
(Date:7/23/2014)... The next episode of “Extreme Weight ... who was physically fit through childhood and adolescence. After ... the heart-wrenching decision to give her son up for ... 18 years, and she punished herself by overeating, gaining ... unique, non-competitive approach to weight loss transformations, “Extreme Weight ...
(Date:7/23/2014)... Inventor and entrepreneur Delegate Joe T. ... the gas pump – sharing his passion for technology ... at Noon. , With 24 patents granted and three ... anyone in the General Assembly since Thomas Jefferson. Inventions ... marker as seen on television, an instrument for measuring ...
(Date:7/23/2014)... A new study supports a growing body of ... natural steroid hormones in treating postmenopausal breast cancer, ... profile than with standard anti-hormone therapies. The study ... the open-access journal Reproductive Biology and Endocrinology ... diagnosed cancer in women in the United States. ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Rich Dad® ... the success of their charity yard sale to support Habit ... raised and 100% of the proceeds will be donated to ... the event are being donated to the Habitat for Humanity ... Myers, Florida 33903. , One of the highlights of ...
Breaking Medicine News(10 mins):Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Celebrating Innovation and Invention 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2
... , THURSDAY, Feb. 23 (HealthDay News) Compared ... of death in elderly patients with dementia, a new ... should aid in dementia care. "This data provides much-needed ... care practitioners treating older demented patients," said Dr. Gisele ...
... HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay News) ... those known to be infected, actually struck many more people ... finds. The actual fatality rate of the H5N1 flu ... millions of people may have been infected over the past ...
... , THURSDAY, Feb. 23 (HealthDay News) -- ... treat children with attention-deficit hyperactivity disorder (ADHD) and other ... study shows. Researchers analyzed data from more than ... assess the use of psychiatric medications in those with ...
... 23 (HealthDay News) -- Noninvasive, CT-guided "virtual" colonoscopy is ... colorectal cancer and precancerous polyps in people 65 and ... called CT colonography, uses virtual-reality technology to produce 3-D ... by many patients, its effectiveness in comparison with invasive ...
... , THURSDAY, Feb. 23 (HealthDay News) -- ... and emergency department visits, improved patient outcomes and saved ... study. Researchers examined the impact of the Community ... families, developed and implemented in 2005 by a team ...
... compound that in laboratory tests blocks inflammation-causing molecules ... cancer and cardiovascular disease without causing harmful toxicity. ... compounds that tamp down so-called reactive oxygen species ... toxicity issues and a lack of specificity in ...
Cached Medicine News:Health News:Certain Antipsychotics Up Risk of Death for Patients With Dementia: Study 2Health News:'Bird' Flu May Be More Common in Humans, But Less Deadly 2Health News:Meds for Autism Not Well Understood: Study 2Health News:Study Supports CT-Based 'Virtual' Colonoscopy to Spot Colon Cancer 2Health News:Study Supports CT-Based 'Virtual' Colonoscopy to Spot Colon Cancer 3Health News:Home-Visit Program May Improve Child's Asthma 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 3
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Each slide contains a gram positive control of Staphylococcus aureus ATCC ® 25923 and a gram negative control of Escherichia coli ATCC ® 25922....
Each slide contains an A.F.B. positive staining control of Mycobacterium scrofulaceum ATCC ® 19981 in simulated sputum and an A.F.B. negative staining control of Escherichia coli ATCC ® 25922...
... The Equalizer With 384 Well Plate Capability ... features of the original Equalizerexpandable and equal tip ... and in-lab calibration capabilities. In addition, this model ... to 4.5mm for loading and accessing many gels ...
Medicine Products: